Abstract 6390: Exploratory biomarker analysis of phase 3 ASTRUM-005 study: Serplulimab versus placebo plus chemotherapy for extensive-stage small cell lung cancer

医学 化疗 生物标志物 安慰剂 阶段(地层学) 癌症 内科学 肿瘤科 肺癌 病理 生物 生物化学 古生物学 替代医学
作者
Ying Cheng,Liang Han,Lin Wu,Jun Chen,Hongmei Sun,Guilan Wen,Yinghua Ji,Anastasia Zimina,Jianhua Shi,Zhijie Pan,Jinsheng Shi,Xicheng Wang,Fang Yang,Xinyi Yang,M. Chen,Shiqi Zhong,Qingyu Wang,Jing Li,Jiancheng Cheng,Ling Chen,Yongqiang Shan,Junwu Zhu
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (6_Supplement): 6390-6390 被引量:1
标识
DOI:10.1158/1538-7445.am2024-6390
摘要

Abstract Background First-line serplulimab plus chemotherapy (chemo) significantly improved OS compared with chemo alone for patients with extensive-stage small cell lung cancer (ES-SCLC) in the phase 3 ASTRUM-005 study. In this exploratory biomarker analysis, we retrospectively evaluated the association of proteome signature, genetic mutations, and hematological indices with efficacy. Methods: Serum proteomics data were generated via Olink® Explore 3072 platform for 168 patients (training: 80; validation: 88). Genetic mutations were assessed by Med1CDxTM panel for 305 patients. Baseline neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) levels were analyzed in all 585 patients. Clinical data cutoff date was June 13, 2022. Results: From Olink data, we generated a 15-protein signature. Results in the validation cohort are shown in the table below. Patients with upper signature score derived higher PFS (7.89 vs 4.17 mo, HR 0.37) and OS (17.18 vs 9.74 mo, HR 0.27) benefit from adding serplulimab, than those with lower signature score (PFS: 4.40 vs 4.34 mo, HR 0.68; OS: 9.05 vs 9.22 mo, HR 0.76). Patients with mutations in RB1 or NOTCH pathway had better tumor responses to the treatment of serplulimab-chemo (ORR: 80% and 86%, respectively) when compared to patients without mutations in RB1 or NOTCH pathway (ORR: 58% and 68%). Patients with NLR ≤4.6, PLR ≤338.3, and LDH ≤ upper limit of normal tended to have longer PFS and OS in both treatment groups; NLR and LDH were further proven to be independent prognostic biomarkers in multivariate regression (P = 0.002 and P <0.001, respectively). Conclusions: We found a 15-protein signature showing predictive power for serplulimab-chemo treatment; RB1 or NOTCH pathway mutations were enriched in serplulimab-chemo responders; baseline NLR and LDH were independent prognostic biomarkers for ES-SCLC. The above findings warrant further investigations. Serplulimab-chemo (n=48) Placebo-chemo (n=40) HR (95% CI) P Upper signature score, n 31 34 Median PFS (95% CI), months 7.89 (1.27, 10.74) 4.17 (2.96, 4.34) 0.37 (0.21, 0.66) <0.001 Median OS (95% CI), months 17.18 (11.01, NE) 9.74 (6.90, 12.65) 0.27 (0.15, 0.50) <0.001 Lower signature score, n 17 6 Median PFS (95% CI), months 4.40 (3.61, 5.75) 4.34 (2.66, NE) 0.68 (0.23, 2.02) 0.488 Median OS (95% CI), months 9.05 (6.67, 11.73) 9.22 (4.53, NE) 0.76 (0.29, 1.98) 0.570 Citation Format: Ying Cheng, Liang Han, Lin Wu, Jun Chen, Hongmei Sun, Guilan Wen, Yinghua Ji, Anastasia Zimina, Jianhua Shi, Zhijie Pan, Jinsheng Shi, Xicheng Wang, Fang Yang, Xinyi Yang, Mengkai Chen, Shiqi Zhong, Qingyu Wang, Jing Li, Jiancheng Cheng, Chen Ling, Yongqiang Shan, Jun Zhu, The ASTRUM-005 Study Group. Exploratory biomarker analysis of phase 3 ASTRUM-005 study: Serplulimab versus placebo plus chemotherapy for extensive-stage small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6390.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LINDENG2004完成签到 ,获得积分10
4秒前
wz完成签到,获得积分10
5秒前
简奥斯汀完成签到 ,获得积分10
12秒前
五本笔记完成签到 ,获得积分10
12秒前
15秒前
花花发布了新的文献求助20
15秒前
asd113发布了新的文献求助10
19秒前
美满的小蘑菇完成签到 ,获得积分10
19秒前
自然白安完成签到 ,获得积分10
25秒前
量子星尘发布了新的文献求助10
28秒前
等待小鸽子完成签到 ,获得积分10
30秒前
龙虾发票完成签到,获得积分10
37秒前
小康学弟完成签到 ,获得积分10
37秒前
了0完成签到 ,获得积分10
37秒前
慕青应助科研通管家采纳,获得10
40秒前
彭于晏应助科研通管家采纳,获得30
40秒前
毛豆爸爸应助科研通管家采纳,获得20
40秒前
林利芳完成签到 ,获得积分0
41秒前
JaneChen完成签到 ,获得积分10
43秒前
健壮惋清完成签到 ,获得积分10
43秒前
44秒前
gabee完成签到 ,获得积分10
48秒前
liang19640908完成签到 ,获得积分10
51秒前
奋斗的雪曼完成签到 ,获得积分10
57秒前
粗心的飞槐完成签到 ,获得积分10
57秒前
LELE完成签到 ,获得积分10
1分钟前
了0完成签到 ,获得积分10
1分钟前
apocalypse完成签到 ,获得积分10
1分钟前
guhao完成签到 ,获得积分10
1分钟前
指导灰完成签到 ,获得积分10
1分钟前
善良的火完成签到 ,获得积分10
1分钟前
优雅夕阳完成签到 ,获得积分10
1分钟前
Jasper应助光亮的自行车采纳,获得10
1分钟前
miki完成签到,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
糖宝完成签到 ,获得积分10
1分钟前
KX2024完成签到,获得积分10
1分钟前
松松发布了新的文献求助20
1分钟前
nusiew完成签到,获得积分10
1分钟前
huiluowork完成签到 ,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022